Diker Bilge, Janneh Omar, van Heeswijk Rolf P G, Copeland Karen F T
Public Health Agency of Canada, 200 Tunney's Pasture Driveway, Ottawa, Ontario, Canada.
Drug Metab Lett. 2010 Dec;4(4):241-5. doi: 10.2174/187231210792928297.
Therapeutic drug monitoring is an important element in the management of drug treatment in HIV-1 infected patients. We have examined the effect of temperature on the egress of HIV-1 protease inhibitors from primary T lymphocytes to determine optimum conditions to be adopted in the processing of blood samples in order to accurately estimate intracellular or plasma drug concentrations. Peripheral blood mononuclear cells or U937 cells were incubated with radiolabelled saquinavir, ritonavir or lopinavir at a concentration of 1 µM. The cells were washed and resuspended in RPMI medium (without radiolabelled drug) and further incubated at 37°C, room temperature (21°C) or at 4°C. We observed that release of drug ensued upon the removal of cells from bathing media containing drug, with the rate of efflux being slower at 4°C and fastest at 37°C for all the protease inhibitors. There was a more rapid efflux of saquinavir and ritonavir than lopinavir from both cultured monocytic and primary human cells. The rank order of the partition coefficient of the drugs were lopinavir > saquinavir > ritonavir. All factors that may limit optimal estimation of cell-associated drug concentrations must be considered so that intracellular concentrations of drug can be accurately estimated.
治疗药物监测是管理HIV-1感染患者药物治疗的重要环节。我们研究了温度对HIV-1蛋白酶抑制剂从原代T淋巴细胞流出的影响,以确定在处理血样时应采用的最佳条件,以便准确估计细胞内或血浆药物浓度。将外周血单核细胞或U937细胞与浓度为1 μM的放射性标记沙奎那韦、利托那韦或洛匹那韦一起孵育。细胞经洗涤后重悬于RPMI培养基(不含放射性标记药物)中,并在37°C、室温(21°C)或4°C下进一步孵育。我们观察到,从含有药物的培养基中取出细胞后,药物会随之释放,对于所有蛋白酶抑制剂,流出速率在4°C时较慢,在37°C时最快。沙奎那韦和利托那韦从培养的单核细胞和原代人细胞中的流出速度比洛匹那韦更快。药物分配系数的排序为洛匹那韦>沙奎那韦>利托那韦。必须考虑所有可能限制对细胞相关药物浓度进行最佳估计的因素,以便能够准确估计细胞内药物浓度。